Role of the akt pathway in prostate cancer

Current Cancer Drug Targets

Volumn 9, Issue 2, 2009, Pages 163-175

  De Souza, Paul L ^a,b   Russell, Pamela J ^b,c   Kearsley, John ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Apoptosis; Cancer progression; Cell signalling; Chemoresistance; Signal transduction

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADAPTOR PROTEIN; ANDROGEN RECEPTOR; CAVEOLIN 1; CAVEOLIN 1 ANTIBODY; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DAIDZEIN; DEFOROLIMUS; DEGEULIN; FLAVONOID; GENISTEIN; ISOLIQUIRITIGENIN; PHENOXODIOL; PROTEIN ANTIBODY; PROTEIN KINASE B; TEMSIROLIMUS; TORC1 PROTEIN; TORC2 PROTEIN; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER RESISTANCE; CELL CYCLE; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; ENZYME PHOSPHORYLATION; HUMAN; NEOPLASM; NONHUMAN; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; ONCOGENE PROTEIN V-AKT; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 62749124909     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909787581006     Document Type: Review

References (168)

1. Shaw, R. J.; Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441, 424-430.
2. Nicholson, K. M.; Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002, 14, 381-395.
3. Staal, S. P.; Hartley, J. W. Thymic lymphoma induction by the AKT8 murine retrovirus. J. Exp. Med. 1988, 167, 1259-1264.
4. Altomare, D. A.; Testa, J. R. Perturbations of the AKT signalling pathway in human cancer. Oncogene 2005, 24, 7455-7464.
5. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-365.
6. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 2002, 296, 1655-1657.
7. Paez, J.; Sellers, W. R. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat. Res. 2003, 115, 145-167.
8. Testa, J. R.; Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 10983-10985.
9. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
10. Luo, J.; Manning, B. D.; Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4, 257-262.
11. Bader, A. G.; Kang, S.; Zhao, L.; Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 2005, 5, 921-929.
12. Samuels, Y.; Diaz, L. A., Jr.; Schmidt-Kittler, O.; Cummins, J. M.; Delong, L.; Cheong, I.; Rago, C.; Huso, D. L.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7, 561-573.
13. Di Cristofano, A.; Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100, 387-390.
14. Dahia, P. L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer 2000, 7, 115-129.
15. Cantley, L. C.; Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 1999, 96, 4240-4245.
16. Leslie, N. R.; Downes, C. P. PTEN: The down side of PI 3-kinase signalling. Cell Signal. 2002, 74, 285-295.
17. Wu, X.; Senechal, K.; Neshat, M. S.; Whang, Y. E.; Sawyers, C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 1998, 95, 15587-15591.
18. Zinda, M. J.; Johnson, M. A.; Paul, J. D.; Horn, C.; Konicek, B. W.; Lu, Z. H.; Sandusky, G.; Thomas, J. E.; Neubauer, B. L.; Lai, M. T.; Graff, J. R. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin. Cancer Res. 2001, 7, 2475-2479.
19. Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Kral, A. M.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.; Robinson, R. G.; Huber, H. E. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 2005, 385, 399-408.
20. Le Page, C.; Koumakpayi, I. H.; Alam-Fahmy, M.; Mes-Masson, A. M.; Saad, F. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br. J. Cancer 2006, 94, 1906-1912.
21. Maroulakou, I. G.; Oemler, W.; Naber, S. P.; Tsichlis, P. N. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007, 67, 167-177.
22. Brazil, D. P.; Yang, Z. Z.; Hemmings, B. A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 2004, 29, 233-242.
23. Gao, T.; Furnari, F.; Newton, A. C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 2005, 78, 13-24.
24. Teruel, T.; Hernandez, R.; Lorenzo, M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001, 50, 2563-2571.
25. Cazzolli, R.; Carpenter, L.; Biden, T. J.; Schmitz-Peiffer, C. A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 2001, 50, 2210-2218.
26. Ivaska, J.; Nissinen, L.; Immonen, N.; Eriksson, J. E.; Kahari, V. M.; Heino, J. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol. Cell. Biol. 2002, 22, 1352-1359.
27. Yellaturu, C. R.; Bhanoori, M.; Neeli, I.; Rao, G. N. N-Ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A. J. Biol. Chem. 2002, 277, 40148-40155.
28. Davidson, B.; Nesland, J. M.; Goldberg, I.; Kopolovic, J.; Gotlieb, W. H.; Bryne, M.; Ben-Baruch, G.; Berner, A.; Reich, R. Caveolin1 expression in advanced-stage ovarian carcinoma-a clinicopathologic study. Gynecol. Oncol. 2001, 81, 166-171.
29. Fine, S. W.; Lisanti, M. P.; Galbiati, F.; Li, M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am. J. Clin. Pathol. 2001, 115, 719-724.
30. Goh, M.; Chen, F.; Paulsen, M. T.; Yeager, A. M.; Dyer, E. S.; Ljungman, M. Phenylbutyrate attenuates the expression of Bcl- X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia 2001, 3, 331-338.
31. Ito, Y.; Yoshida, H.; Nakano, K.; Kobayashi, K.; Yokozawa, T.; Hirai, K.; Matsuzuka, F.; Matsuura, N.; Kakudo, K.; Kuma, K.; Miyauchi, A. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br. J. Cancer 2002, 86, 912-916.
32. Kato, K.; Hida, Y.; Miyamoto, M.; Hashida, H.; Shinohara, T.; Itoh, T.; Okushiba, S.; Kondo, S.; Katoh, H. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002, 94, 929-933.
33. Rajjayabun, P. H.; Garg, S.; Durkan, G. C.; Charlton, R.; Robinson, M. C.; Mellon, J. K. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001, 58, 811-814.
34. Tso, C. L.; McBride, W. H.; Sun, J.; Patel, B.; Tsui, K. H.; Paik, S. H.; Gitlitz, B.; Caliliw, R.; van Ophoven, A.; Wu, L.; deKernion, J.; Belldegrun, A. Androgen deprivation induces selective out-growth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000, 6, 220-233.
35. Yang, C. P.; Galbiati, F.; Volonte, D.; Horwitz, S. B.; Lisanti, M. P. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 1998, 439, 368-372.
36. Tahir, S. A.; Yang, G.; Ebara, S.; Timme, T. L.; Satoh, T.; Li, L.; Goltsov, A.; Ittmann, M.; Morrisett, J. D.; Thompson, T. C. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001, 67, 3882-3885.
37. Ikonen, E.; Heino, S.; Lusa, S. Caveolins and membrane cholesterol. Biochem. Soc. Trans. 2004, 32, 121-123.
38. Schroeder, F.; Gallegos, A. M.; Atshaves, B. P.; Storey, S. M.; McIntosh, A. L.; Petrescu, A. D.; Huang, H.; Starodub, O.; Chao, H.; Yang, H.; Frolov, A.; Kier, A. B. Recent advances in membrane microdomains: rafts, caveolae, and intracellular cholesterol trafficking. Exp. Biol. Med. (Maywood) 2001, 226, 873-890.
39. Sternberg, P. W.; Schmid, S. L. Caveolin, cholesterol and Ras signalling. Nat. Cell Biol. 1999, 1, E35-37.
40. Li, L.; Ren, C. H.; Tahir, S. A.; Ren, C.; Thompson, T. C. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell. Biol. 2003, 23, 9389-9404.
41. Kaestner, K. H.; Knochel, W.; Martinez, D. E. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 2000, 74, 142-146.
42. Greer, E. L.; Brunet, A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24, 7410-7425.
43. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Fork-head transcription factor. Cell 1999, 96, 857-868.
44. Brunet, A.; Kanai, F.; Stehn, J.; Xu, J.; Sarbassova, D.; Frangioni, J. V.; Dalal, S. N.; DeCaprio, J. A.; Greenberg, M. E.; Yaffe, M. B. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J. Cell Biol. 2002, 756, 817-828.
45. Plas, D. R.; Thompson, C. B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 2003, 278, 12361-12366.
46. Hu, M. C.; Lee, D. F.; Xia, W.; Golfman, L. S.; Ou-Yang, F.; Yang, J. Y.; Zou, Y.; Bao, S.; Hanada, N.; Saso, H.; Kobayashi, R.; Hung, M. C. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004, 117, 225-237.
47. Karin, M.; Cao, Y.; Greten, F. R.; Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2, 301-310.
48. Romashkova, J. A.; Makarov, S. S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401, 86-90.
49. Dan, H. C.; Sun, M.; Yang, L.; Feldman, R. I.; Sui, X. M.; Ou, C. C.; Nellist, M.; Yeung, R. S.; Halley, D. J.; Nicosia, S. V.; Pledger, W. J.; Cheng, J. Q. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 2002, 277, 35364-35370.
50. Garami, A.; Zwartkruis, F. J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Kozma, S. C.; Hafen, E.; Bos, J. L.; Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell, 2003, 11, 1457-1466.
51. Inoki, K.; Li, Y.; Xu, T.; Guan, K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17, 1829-1834.
52. Zhang, Y.; Gao, X.; Saucedo, L. J.; Ru, B.; Edgar, B. A.; Pan, D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 2003, 5, 578-581.
53. Schmelzle, T.; Hall, M. N. TOR, a central controller of cell growth. Cell 2000, 103, 253-262.
54. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098-1101.
55. Ma, L.; Chen, Z.; Erdjument-Bromage, H.; Tempst, P.; Pandolfi, P. P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121, 179-193.
56. Chrivia, J. C.; Kwok, R. P.; Lamb, N.; Hagiwara, M.; Montminy, M. R.; Goodman, R. H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993, 365, 855-859.
57. Wilson, B. E.; Mochon, E.; Boxer, L. M. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol. Cell. Biol. 1996, 16, 5546-5556.
58. Grimes, C. A.; Jope, R. S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65, 391-426.
59. Tanno, S.; Tanno, S.; Mitsuuchi, Y.; Altomare, D. A.; Xiao, G. H.; Testa, J. R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001, 61, 589-593.
60. Mayo, L. D.; Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 2001, 98, 11598-11603.
61. Moumen, A.; Patane, S.; Porras, A.; Dono, R.; Maina, F. Met acts on Mdm2 via mTOR to signal cell survival during development. Development 2007, 134, 1443-1451.
62. Mayo, L. D.; Dixon, J. E.; Durden, D. L.; Tonks, N. K.; Donner, D. B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 2002, 277, 5484-5489.
63. Chang, C. J.; Freeman, D. J.; Wu, H. PTEN regulates Mdm2 expression through the P1 promoter. J. Biol. Chem. 2004, 279, 29841-29848.
64. Gnanapragasam, V. J.; Leung, H. Y.; Pulimood, A. S.; Neal, D. E.; Robson, C. N. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br. J. Cancer 2001, 85, 1928-1936.
65. Zhou, G.; Hashimoto, Y.; Kwak, I.; Tsai, S. Y.; Tsai, M. J. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol. Cell. Biol. 2003, 23, 7742-7755.
66. Wen, Y.; Hu, M. C.; Makino, K.; Spohn, B.; Bartholomeusz, G.; Yan, D. H.; Hung, M. C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000, 60, 6841-6845.
67. Chesire, D. R.; Ewing, C. M.; Gage, W. R.; Isaacs, W. B. In vitro evidence for complex modes of nuclear beta-catenin signalling during prostate growth and tumorigenesis. Oncogene 2002, 21, 2679-2694.
68. Salas, T. R.; Kim, J.; Vakar-Lopez, F.; Sabichi, A. L.; Troncoso, P.; Jenster, G.; Kikuchi, A.; Chen, S. Y.; Shemshedini, L.; Suraokar, M.; Logothetis, C. J.; DiGiovanni, J.; Lippman, S. M.; Menter, D. G. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J. Biol. Chem. 2004, 279, 19191-19200.
69. Wang, Y.; Kreisberg, J. I.; Ghosh, P. M. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr. Cancer Drug Targets 2007, 7, 591-604.
70. Reddy, G. P.; Barrack, E. R.; Dou, Q. P.; Menon, M.; Pelley, R.; Sarkar, F. H.; Sheng, S. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J. Cell Biochem. 2006, 98, 1408-1423.
71. Li, Y.; Koeneman, K. S. Phosphoinositide 3-kinase-independent nongenomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains Cinar B, Mukhopadhyay NK, Meng G, Freeman MR, Urological Diseases Research Center, Departments of Urology, Surgery, Biological Chemistry, and Molecular Pharmacology, Children's Hospital Boston, Harvard Medical School, Boston, MA. Urol. Oncol. 2008, 26, 107-108.
72. Cinar, B.; Mukhopadhyay, N. K.; Meng, G.; Freeman, M. R. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J. Biol. Chem. 2007, 282, 29584-29593.
73. Lin, H. K.; Hu, Y. C.; Lee, D. K.; Chang, C. Regulation of androgen receptor signalling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol. Endocrinol. (Baltimore) 2004, 18, 2409-2423.
74. Manin, M.; Baron, S.; Goossens, K.; Beaudoin, C.; Jean, C.; Veyssiere, G.; Verhoeven, G.; Morel, L. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem. J. 2002, 366, 729-736.
75. Lin, H. K.; Yeh, S.; Kang, H. Y.; Chang, C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA 2001, 98, 7200-7205.
76. Yang, L.; Xie, S.; Jamaluddin, M. S.; Altuwaijri, S.; Ni, J.; Kim, E.; Chen, Y. T.; Hu, Y. C.; Wang, L.; Chuang, K. H.; Wu, C. T.; Chang, C. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J. Biol. Chem. 2005, 280, 33558-33565.
77. Vinall, R. L.; Hwa, K.; Ghosh, P.; Pan, C. X.; Lara, P. N., Jr.; de Vere White, R. W. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin. Cancer Res. 2007, 13, 6204-6216.
78. Xin, L.; Teitell, M. A.; Lawson, D. A.; Kwon, A.; Mellinghoff, I. K.; Witte, O. N. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc. Natl. Acad. Sci. USA 2006, 103, 7789-7794.
79. Mikhailova, M.; Wang, Y.; Bedolla, R.; Lu, X. H.; Kreisberg, J. I.; Ghosh, P. M. AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer. Adv. Exp. Med. Biol. 2008, 617, 397-405.
80. Xu, Y.; Chen, S. Y.; Ross, K. N.; Balk, S. P. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 2006, 66, 7783-7792.
81. Shimizu, Y.; Segawa, T.; Inoue, T.; Shiraishi, T.; Yoshida, T.; Toda, Y.; Yamada, T.; Kinukawa, N.; Terada, N.; Kobayashi, T.; Kinoshita, H.; Kamoto, T.; Nakamura, E.; Ogawa, O. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU 2007, 100, 685-690.
82. Plas, D. R.; Thompson, C. B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005, 24, 7435-7442.
83. Burgering, B. M.; Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376, 599-602.
84. Barnes, K.; McIntosh, E.; Whetton, A. D.; Daley, G. Q.; Bentley, J.; Baldwin, S. A. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 2005, 24, 3257-3267.
85. Bernal-Mizrachi, E.; Fatrai, S.; Johnson, J. D.; Ohsugi, M.; Otani, K.; Han, Z.; Polonsky, K. S.; Permutt, M. A. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. J. Clin. Invest. 2004, 114, 928-936.
86. Elstrom, R. L.; Bauer, D. E.; Buzzai, M.; Karnauskas, R.; Harris, M. H.; Plas, D. R.; Zhuang, H.; Cinalli, R. M.; Alavi, A.; Rudin, C. M.; Thompson, C. B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64, 3892-3899.
87. Plas, D. R.; Talapatra, S.; Edinger, A. L.; Rathmell, J. C.; Thompson, C. B. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J. Biol. Chem. 2001, 276, 12041-12048.
88. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231-241.
89. Yamaguchi, H.; Wang, H. G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001, 20, 7779-7786.
90. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282, 1318-1321.
91. Thant, A. A.; Nawa, A.; Kikkawa, F.; Ichigotani, Y.; Zhang, Y.; Sein, T. T.; Amin, A. R.; Hamaguchi, M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin. Exp. Metastasis 2000, 18, 423-428.
92. Chan, J.; Bayliss, P. E.; Wood, J. M.; Roberts, T. M. Dissection of angiogenic signalling in zebrafish using a chemical genetic approach. Cancer Cell 2002, 1, 257-267.
93. Zhou, B. P.; Hung, M. C. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin. Oncol. 2002, 29, 62-70.
94. Viglietto, G.; Motti, M. L.; Bruni, P.; Melillo, R. M.; D'Alessio, A.; Califano, D.; Vinci, F.; Chiappetta, G.; Tsichlis, P.; Bellacosa, A.; Fusco, A.; Santoro, M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 2002, 8, 1136-1144.
95. Graff, J. R.; Konicek, B. W.; McNulty, A. M.; Wang, Z.; Houck, K.; Allen, S.; Paul, J. D.; Hbaiu, A.; Goode, R. G.; Sandusky, G. E.; Vessella, R. L.; Neubauer, B. L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 2000, 275, 24500-24505.
96. Giri, D.; Ittmann, M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum. Pathol. 1999, 30, 419-424.
97. Koul, D.; Shen, R.; Garyali, A.; Ke, L. D.; Liu, T. J.; Yung, W. K. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int. J. Oncol. 2002, 21, 469-475.
98. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399, 601-605.
99. Fulton, D.; Gratton, J. P.; McCabe, T. J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T. F.; Papapetropoulos, A.; Sessa, W. C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399, 597-601.
100. Arsham, A. M.; Plas, D. R.; Thompson, C. B.; Simon, M. C. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 2004, 64, 3500-3507.
101. Edwards, J.; Krishna, N. S.; Witton, C. J.; Bartlett, J. M. Gene amplifications associated with the development of hormone- resistant prostate cancer. Clin. Cancer Res. 2003, 9, 5271-5281.
102. Bellacosa, A.; de Feo, D.; Godwin, A. K.; Bell, D. W.; Cheng, J. Q.; Altomare, D. A.; Wan, M.; Dubeau, L.; Scambia, G.; Masciullo, V.; Ferrandina, G.; Benedetti Panici, P.; Mancuso, S.; Neri, G.; Testa, J. R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 64, 280-285.
103. Cheng, J. Q.; Godwin, A. K.; Bellacosa, A.; Taguchi, T.; Franke, T. F.; Hamilton, T. C.; Tsichlis, P. N.; Testa, J. R. AKT2, a putative oncogene encoding a member of a subfamily of protein- serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 1992, 89, 9267-9271.
104. Nakatani, K.; Thompson, D. A.; Barthel, A.; Sakaue, H.; Liu, W.; Weigel, R. J.; Roth, R. A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999, 274, 21528-21532.
105. Sun, M.; Wang, G.; Paciga, J. E.; Feldman, R. I.; Yuan, Z. Q.; Ma, X. L.; Shelley, S. A.; Jove, R.; Tsichlis, P. N.; Nicosia, S. V.; Cheng, J. Q. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 2001, 159, 431-437.
106. Liao, Y.; Grobholz, R.; Abel, U.; Trojan, L.; Michel, M. S.; Angel, P.; Mayer, D. Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int. J. Cancer 2003, 107, 676-680.
107. Edwards, J.; Traynor, P.; Munro, A. F.; Pirret, C. F.; Dunne, B.; Bartlett, J. M. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin. Cancer Res. 2006, 12, 123-130.
108. Deocampo, N. D.; Huang, H.; Tindall, D. J. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. 2003, 28, 145-153.
109. Dong, J. T. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 2001, 20, 173-193.
110. Latini, J. M.; Rieger-Christ, K. M.; Wang, D. S.; Silverman, M. L.; Libertino, J. A.; Summerhayes, I. C. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions. J. Urol. 2001, 166, 1931-1936.
111. Rubin, M. A.; Gerstein, A.; Reid, K.; Bostwick, D. G.; Cheng, L.; Parsons, R.; Papadopoulos, N. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum. Pathol. 2000, 31, 504-508.
112. Gray, I. C.; Stewart, L. M.; Phillips, S. M.; Hamilton, J. A.; Gray, N. E.; Watson, G. J.; Spurr, N. K.; Snary, D. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer 1998, 78, 1296-1300.
113. Pesche, S.; Latil, A.; Muzeau, F.; Cussenot, O.; Fournier, G.; Longy, M.; Eng, C.; Lidereau, R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998, 16, 2879-2883.
114. Feilotter, H. E.; Nagai, M. A.; Boag, A. H.; Eng, C.; Mulligan, L. M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998, 16, 1743-1748.
115. Rennie, P. S.; Nelson, C. C. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev. 1998, 17, 401-409.
116. Whang, Y. E.; Wu, X.; Suzuki, H.; Reiter, R. E.; Tran, C.; Vessella, R. L.; Said, J. W.; Isaacs, W. B.; Sawyers, C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 1998, 95, 5246-5250.
117. Li, L.; Ittmann, M. M.; Ayala, G.; Tsai, M. J.; Amato, R. J.; Wheeler, T. M.; Miles, B. J.; Kadmon, D.; Thompson, T. C. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005, 8, 108-118.
118. Wang, S.; Gao, J.; Lei, Q.; Rozengurt, N.; Pritchard, C.; Jiao, J.; Thomas, G. V.; Li, G.; Roy-Burman, P.; Nelson, P. S.; Liu, X.; Wu, H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4, 209-221.
119. Yang, G.; Ayala, G.; De Marzo, A.; Tian, W.; Frolov, A.; Wheeler, T. M.; Thompson, T. C.; Harper, J. W. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. 2002, 8, 3419-3426.
120. McMenamin, M. E.; Soung, P.; Perera, S.; Kaplan, I.; Loda, M.; Sellers, W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59, 4291-4296.
121. Ayala, G.; Thompson, T.; Yang, G.; Frolov, A.; Li, R.; Scardino, P.; Ohori, M.; Wheeler, T.; Harper, W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. 2004, 10, 6572-6578.
122. Kreisberg, J. I.; Malik, S. N.; Prihoda, T. J.; Bedolla, R. G.; Troyer, D. A.; Kreisberg, S.; Ghosh, P. M. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004, 64, 5232-5236.
123. Assikis, V. J.; Do, K. A.; Wen, S.; Wang, X.; Cho-Vega, J. H.; Brisbay, S.; Lopez, R.; Logothetis, C. J.; Troncoso, P.; Papandreou, C. N.; McDonnell, T. J. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin. Cancer Res. 2004, 10, 6770-6778.
124. Schmitz, M.; Grignard, G.; Margue, C.; Dippel, W.; Capesius, C.; Mossong, J.; Nathan, M.; Giacchi, S.; Scheiden, R.; Kieffer, N. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int. J. Cancer 2007, 120, 1284-1292.
125. Li, B.; Sun, A.; Youn, H.; Hong, Y.; Terranova, P. F.; Thrasher, J. B.; Xu, P.; Spencer, D. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 2007, 28, 572-583.
126. Ghosh, P. M.; Malik, S. N.; Bedolla, R. G.; Wang, Y.; Mikhailova, M.; Prihoda, T. J.; Troyer, D. A.; Kreisberg, J. I. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr. Relat. Cancer 2005, 12, 119-134.
127. Shi, Y.; Chatterjee, S. J.; Brands, F. H.; Shi, S. R.; Pootrakul, L.; Taylor, C. R.; Datar, R.; Cote, R. J. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU 2006, 97, 170-178.
128. Gao, H.; Ouyang, X.; Banach-Petrosky, W. A.; Gerald, W. L.; Shen, M. M.; Abate-Shen, C. Combinatorial activities of Akt and B-Raf/Erk signalling in a mouse model of androgen-independent prostate cancer. Proc. Natl. Acad. Sci. USA 2006, 103, 14477-14482.
129. Levine, B. Cell biology: autophagy and cancer. Nature 2007, 446, 745-747.
130. Jin, S.; DiPaola, R. S.; Mathew, R.; White, E. Metabolic catastrophe as a means to cancer cell death. J. Cell Sci. 2007, 120, 379-383.
131. Takeuchi, H.; Kondo, Y.; Fujiwara, K.; Kanzawa, T.; Aoki, H.; Mills, G. B.; Kondo, S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005, 65, 3336-3346.
132. Aoki, H.; Takada, Y.; Kondo, S.; Sawaya, R.; Aggarwal, B.; Kondo, Y. Evidence That Curcumin Suppresses the Growth of Malignant Gliomas In vitro and In vivo Through Induction of Autophagy: Role of Akt and ERK Signalling Pathways. Mol. Pharmacol. 2007, 72, 29-39.
133. Gossner, G.; Choi, M.; Tan, L.; Fogoros, S.; Griffith, K. A.; Kuenker, M.; Liu, J. R. Genistein-induced apoptosis and auto-phagocytosis in ovarian cancer cells. Gynecol. Oncol. 2007, 105, 23-30.
134. Cao, C.; Subhawong, T.; Albert, J. M.; Kim, K. W.; Geng, L.; Sekhar, K. R.; Gi, Y. J.; Lu, B. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006, 66, 10040-10047.
135. Lavieu, G.; Scarlatti, F.; Sala, G.; Carpentier, S.; Levade, T.; Ghidoni, R.; Botti, J.; Codogno, P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J. Biol. Chem. 2006, 281, 8518-8527.
136. Arico, S.; Petiot, A.; Bauvy, C.; Dubbelhuis, P. F.; Meijer, A. J.; Codogno, P.; Ogier-Denis, E. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 2001, 276, 35243-35246.
137. Jung, J. I.; Chung, E.; Seon, M. R.; Shin, H. K.; Kim, E. J.; Lim, S. S.; Chung, W. Y.; Park, K. K.; Park, J. H. Isoliquiritigenin (ISL) inhibits ErbB3 signalling in prostate cancer cells. BioFactors (Oxford, England), 2006, 28, 159-168.
138. Easton, J. B.; Houghton, P. J. Therapeutic potential of target of rapamycin inhibitors. Exp. Opin. Ther. Targets 2004, 8, 551-564.
139. Easton, J. B.; Houghton, P. J. mTOR and cancer therapy. Oncogene 2006, 25, 6436-6446.
140. Yu, K.; Toral-Barza, L.; Discafani, C.; Zhang, W. G.; Skotnicki, J.; Frost, P.; Gibbons, J. J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 2001, 8, 249-258.
141. Neshat, M. S.; Mellinghoff, I. K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.; Gibbons, J. J.; Wu, H.; Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 2001, 98, 10314-10319.
142. Podsypanina, K.; Lee, R. T.; Politis, C.; Hennessy, I.; Crane, A.; Puc, J.; Neshat, M.; Wang, H.; Yang, L.; Gibbons, J.; Frost, P.; Dreisbach, V.; Blenis, J.; Gaciong, Z.; Fisher, P.; Sawyers, C.; Hedrick-Ellenson, L.; Parsons, R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA 2001, 98, 10320-10325.
143. Dudkin, L.; Dilling, M. B.; Cheshire, P. J.; Harwood, F. C.; Hollingshead, M.; Arbuck, S. G.; Travis, R.; Sausville, E. A.; Houghton, P. J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 2001, 7, 1758-1764.
144. Sun, S. Y.; Rosenberg, L. M.; Wang, X.; Zhou, Z.; Yue, P.; Fu, H.; Khuri, F. R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65, 7052-7058.
145. O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res. 2006, 66, 1500-1508.
146. Tanaka, M.; Rosser, C. J.; Grossman, H. B. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detec. Preven. 2005, 29, 170-174.
147. Boulay, A.; Rudloff, J.; Ye, J.; Zumstein-Mecker, S.; O'Reilly, T.; Evans, D. B.; Chen, S.; Lane, H. A. Dual inhibition of mTOR and estrogen receptor signalling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005, 11, 5319-5328.
148. Tanaka, M.; Koul, D.; Davies, M. A.; Liebert, M.; Steck, P. A.; Grossman, H. B. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000, 19, 5406-5412.
149. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Janne, P. A. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 2007, 316, 1039-43.
150. Kim, S. H.; Juhnn, Y. S.; Song, Y. S. Akt involvement in Paclitaxel chemoresistance of human ovarian cancer cells. Ann. N.Y. Acad. Sci. 2007, 1095, 82-89.
151. Beuvink, I.; Boulay, A.; Fumagalli, S.; Zilbermann, F.; Ruetz, S.; O'Reilly, T.; Natt, F.; Hall, J.; Lane, H. A.; Thomas, G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120, 747-759.
152. Brown, D. M.; Kelly, G. E.; Husband, A. J. Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol.
153. Kelly, G. E.; Husband, A. J. Flavonoid compounds in the prevention and treatment of prostate cancer. Methods Mol. Med. 2003, 81, 377-394.
154. Sarkar, F. H.; Adsule, S.; Padhye, S.; Kulkarni, S.; Li, Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem. 2006, 6, 401-407.
155. Sarkar, F. H.; Li, Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 2002, 21, 265-280.
156. Pollard, M.; Suckow, M. A. Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model. Comp. Med. 2006, 56, 461-467.
157. Hussain, M.; Banerjee, M.; Sarkar, F. H.; Djuric, Z.; Pollak, M. N.; Doerge, D.; Fontana, J.; Chinni, S.; Davis, J.; Forman, J.; Wood, D. P.; Kucuk, O. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer 2003, 47, 111-117.
158. Cao, F.; Jin, T. Y.; Zhou, Y. F. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed. Environ. Sci. 2006, 19, 35-41.
159. Tepper, C. G.; Vinall, R. L.; Wee, C. B.; Xue, L.; Shi, X. B.; Burich, R.; Mack, P. C.; de Vere White, R. W. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate 2007, 67, 521-535.
160. Bemis, D. L.; Capodice, J. L.; Desai, M.; Buttyan, R.; Katz, A. E. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin. Cancer Res. 2004, 10, 5282-5292.
161. Guo, Y.; Wang, S.; Hoot, D. R.; Clinton, S. K. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J. Nutr. Biochem. 2007, 18, 408-417.
162. Dell'Eva, R.; Ambrosini, C.; Minghelli, S.; Noonan, D. M.; Albini, A.; Ferrari, N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis 2007, 28, 404-413.
163. Kamsteeg, M.; Rutherford, T.; Sapi, E.; Hanczaruk, B.; Shahabi, S.; Flick, M.; Brown, D.; Mor, G. Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003, 22, 2611-2620.
164. Yu, F.; Watts, R. N.; Zhang, X. D.; Borrow, J. M.; Hersey, P. Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells. Anticancer Drugs 2006, 17, 1151-1161.
165. Alvero, A. B.; O'Malley, D.; Brown, D.; Kelly, G.; Garg, M.; Chen, W.; Rutherford, T.; Mor, G. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006, 106, 599-608.
166. Sapi, E.; Alvero, A. B.; Chen, W.; O'Malley, D.; Hao, X. Y.; Dwipoyono, B.; Garg, M.; Kamsteeg, M.; Rutherford, T.; Mor, G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol. Res. 2004, 14, 567-578.
167. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125-134.
168. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T.; Chen, I.; Bycott, P. W.; Baum, C. M.; Figlin, R. A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 115-124.